» Articles » PMID: 15479475

In Vitro Pharmacokinetics of Anti-psoriatic Fumaric Acid Esters

Overview
Journal BMC Pharmacol
Publisher Biomed Central
Specialty Pharmacology
Date 2004 Oct 14
PMID 15479475
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Psoriasis is a chronic inflammatory skin disease that can be successfully treated with a mixture of fumaric acid esters (FAE) formulated as enteric-coated tablets for oral use. These tablets consist of dimethylfumarate (DMF) and salts of monoethylfumarate (MEF) and its main bioactive metabolite is monomethylfumarate (MMF). Little is known about the pharmacokinetics of these FAE. The aim of the present study was to investigate the hydrolysis of DMF to MMF and the stability of MMF, DMF and MEF at in vitro conditions representing different body compartments.

Results: DMF is hydrolyzed to MMF in an alkaline environment (pH 8), but not in an acidic environment (pH 1). In these conditions MMF and MEF remained intact during the period of analysis (6 h). Interestingly, DMF was hardly hydrolyzed to MMF in a buffer of pH 7.4, but was rapidly hydrolyzed in human serum having the same pH. Moreover, in whole blood the half-life of DMF was dramatically reduced as compared to serum. The concentrations of MMF and MEF in serum and whole blood decreased with increasing time. These data indicate that the majority of the FAE in the circulation are metabolized by one or more types of blood cells. Additional experiments with purified blood cell fractions resuspended in phosphate buffered saline (pH 7.4) revealed that at concentrations present in whole blood monocytes/lymphocytes, but not granulocytes and erythrocytes, effectively hydrolyzed DMF to MMF. Furthermore, in agreement with the data obtained with the pure components of the tablet, the enteric-coated tablet remained intact at pH 1, but rapidly dissolved at pH 8.

Conclusion: Together, these in vitro data indicate that hydrolysis of DMF to MMF rapidly occurs at pH 8, resembling that within the small intestines, but not at pH 1 resembling the pH in the stomach. At both pHs MMF and MEF remained intact. These data explain the observation that after oral FAE intake MMF and MEF, but not DMF, can be readily detected in the circulation of human healthy volunteers and psoriasis patients.

Citing Articles

Nrf2-Independent Anti-Inflammatory Effects of Dimethyl Fumarate: Challenges and Prospects in Developing Electrophilic Nrf2 Activators for Neurodegenerative Diseases.

Izumi Y, Koyama Y Antioxidants (Basel). 2025; 13(12.

PMID: 39765855 PMC: 11727036. DOI: 10.3390/antiox13121527.


Dimethyl Fumarate-Loaded Gellan Gum Hydrogels Can Reduce In Vitro Chemokine Expression in Oral Cells.

Wang L, Dos Santos Sanches N, Panahipour L, Imani A, Yao Y, Zhang Y Int J Mol Sci. 2024; 25(17).

PMID: 39273432 PMC: 11395421. DOI: 10.3390/ijms25179485.


Revisiting the Injury Mechanism of Goat Sperm Caused by the Cryopreservation Process from a Perspective of Sperm Metabolite Profiles.

Li C, Lv C, Larbi A, Liang J, Yang Q, Wu G Int J Mol Sci. 2024; 25(16).

PMID: 39201798 PMC: 11354876. DOI: 10.3390/ijms25169112.


Selective activation of cellular stress response pathways by fumaric acid esters.

Erler K, Krafczyk N, Steinbrenner H, Klotz L FEBS Open Bio. 2024; 14(8):1230-1246.

PMID: 38794848 PMC: 11301269. DOI: 10.1002/2211-5463.13833.


Bariatric surgery and dimethyl fumarate-induced lymphopenia in patients with multiple sclerosis.

Andreozzi V, Capuano R, Scannapieco S, Barra F, DArco B, Giordano C Neurol Sci. 2023; 45(6):2807-2810.

PMID: 38150132 DOI: 10.1007/s10072-023-07283-w.


References
1.
van der Schroeff J, Hermans J, SUURMOND D . Fumaric acid therapy for psoriasis: a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. 1990; 22(2 Pt 1):311-2. DOI: 10.1016/s0190-9622(08)80766-9. View

2.
Litjens N, Burggraaf J, van Strijen E, van Gulpen C, Mattie H, Schoemaker R . Pharmacokinetics of oral fumarates in healthy subjects. Br J Clin Pharmacol. 2004; 58(4):429-32. PMC: 1884599. DOI: 10.1111/j.1365-2125.2004.02145.x. View

3.
Altmeyer P, Matthes U, Pawlak F, Hoffmann K, Frosch P, Ruppert P . Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol. 1994; 30(6):977-81. DOI: 10.1016/s0190-9622(94)70121-0. View

4.
Koo J, Lee J . Cyclosporine: what clinicians need to know. Dermatol Clin. 1995; 13(4):897-907. View

5.
de Jong R, Bezemer A, Zomerdijk T, Ottenhoff T, Nibbering P . Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur J Immunol. 1996; 26(9):2067-74. DOI: 10.1002/eji.1830260916. View